Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Biocodex To Present New Data at the American Epilepsy Society (AES) 2025 Annual Meeting


      News provided by

      Biocodex, Inc.

      Dec 01, 2025, 09:00 ET

      Share this article

      Share this article


      BEDMINSTER, N.J., Dec. 1, 2025 /PRNewswire/ -- Biocodex, a global pharmaceutical company and long-time pioneer in the treatment of rare pediatric diseases, will present 12 studies at the upcoming AES 2025 Annual Meeting in Atlanta, Georgia, December 5-9. The studies focus on the use of stiripentol and its impact on patients with Dravet syndrome.

      Carla Schad, MD, Biocodex North American Medical Officer, previewed what providers can expect to see from Biocodex at AES this year.

      Continue Reading
      DIACOMIT (stiripentol) is indicated for the treatment of seizures associated with Dravet syndrome in patients taking clobazam and who are 6 months of age or older and weigh 15 pounds or more. There are no clinical data to support the use of DIACOMIT alone in Dravet syndrome.
      DIACOMIT (stiripentol) is indicated for the treatment of seizures associated with Dravet syndrome in patients taking clobazam and who are 6 months of age or older and weigh 15 pounds or more. There are no clinical data to support the use of DIACOMIT alone in Dravet syndrome.

      "Biocodex USA is thrilled to be attending AES this year. We are dedicated to bringing new data to our healthcare providers and researchers; but most importantly, our AES attendance will highlight our partnerships with thought leaders and advocates. At Biocodex, our commitment and promise are to always keep the patient first."

      Key scientific and patient-focused data includes:

      Poster Number

      Poster Title

      Poster on Display

      Author Present Time

      1.386

      Real-World Use and
      Effectiveness of Stiripentol
      in U.S. Patients With
      Dravet Syndrome: Results
      from the STIRUS Study

      Saturday December 6,
      Session 1, Noon – 6
      PM, Exhibit Hall B2

      Noon – 2 PM

      1.39

      Long-Term Effectiveness
      of Stiripentol in Reducing
      Seizure Burden and Status
      Epilepticus in Dravet
      Syndrome: Results From
      a 3-Year Japanese Post-
      Marketing Surveillance

      2.107

      Evaluating Current
      Practices and
      Communication
      Surrounding Sudden
      Unexpected Death
      in Epilepsy (SUDEP)

      Sunday December 7,
      Session 2, 10 AM – 4
      PM, Exhibit Hall B2

      Noon – 2 PM

      2.426

      Need for Reintroduction of
      Stiripentol After Weaning
      in Patients With Dravet
      Syndrome: A Multicenter
      Case Series

      2.436

      Stiripentol Use in Dravet
      Syndrome Is Associated
      With Lower Mortality Rates
      in a Real-World Cohort

      2.444

      Practical Consensus
      Recommendations for
      Rational Polytherapy
      Involving Stiripentol in
      Dravet Syndrome: Results
      of a US Cohort

      2.446

      Underutilization of FDA-
      Approved Dravet
      Syndrome Specific
      Therapies: Findings From 
      a US Multi-Center Survey
      and Advisory Board

      2.452

      Real-World Utilization of
      Stiripentol (STP) by United
      States (US) Prescribers: A
      3-Year Analysis Update

      3.374

      Efficacy and Tolerability of
      Stiripentol Across Non-
      Dravet Developmental and
      Epileptic
      Encephalopathies: A
      Literature Review Including
      Genetic and Syndromic Epilepsies 

      Monday December 8,
      Session 3, 8 AM – 2
      PM, Poster Hall B3

      Noon – 1:45 PM

      3.375

      Real-World Utilization of
      Stiripentol in Children
      Aged Three Years and
      Younger: A US
      Perspective

      3.382

      Practical Consensus
      Recommendations for
      Polytherapy Involving
      Stiripentol in Dravet
      Syndrome: A Nominal
      Group Approach

      3.436

      Stiripentol Use in Lennox-
      Gastaut Syndrome:
      Results From a Phase 2
      Clinical Trial

      Symposia Programs at the AES 2025 Annual Meeting

      Biocodex will be hosting two informational symposia at this conference, focusing on the following:

      Symposia
      Title

      Description

      Speaker

      Date, Time,
      Location

      Diagnostic and
      Treatment
      Disparities in
      Dravet
      Syndrome

      In this fireside chat-style program,
      recent data regarding the diagnostic
      and treatment disparities in Dravet
      syndrome will be examined.

      Recommended guidelines developed
      by leading epileptologists routinely
      treating Dravet will be shared with
      the audience on how to accurately
      diagnose and properly treat Dravet
      syndrome for optimal outcomes.

      Julie Ziobro, MD,
      PhD,
      Assistant Professor
      of Pediatrics
      Division of Pediatric
      Neurology,
      University of
      Michigan, Ann Arbor

      Mary Anne Meskis,
      Chief Executive
      Officer,
      Dravet Syndrome
      Foundation

      Kelly Gwin, PharmD,
      Director, Field
      Medical Affairs,
      Biocodex Inc.

      Saturday,
      December 6,

      1:30 PM –
      2:30 PM,

      Georgia
      World
      Congress
      Center,
      Product
      Theater 2, in
      the Exhibit
      Hall

      Optimizing a
      Treatment
      Option for
      Patients With
      Dravet Syndrome

      An informative presentation that
      discusses the impact of Dravet
      syndrome, signs and symptoms of
      the disease, as well as the
      importance of early intervention.
      Learn about an approved therapy for
      patients with Dravet syndrome.

      James W. Wheless,
      BScPharm, MD,
      FAAP, FACP, FAAN,
      FAES

      Saturday,
      December 6,

      3:30 PM –
      4:30 PM,

      Georgia
      World
      Congress
      Center,
      Product
      Theater 2, in
      the Exhibit
      Hall

      About Dravet Syndrome

      Dravet syndrome is a rare and severe genetic epilepsy that most commonly begins before the age of one, when an otherwise normally developing child begins having frequent, prolonged seizures.1 These seizures can cause lasting damage, which over time can lead to developmental and cognitive delays affecting coordination, language, and behavior.2 Its incidence is estimated to be 1 in 16,000 births.3

      About Biocodex

      Founded in 1953, Biocodex is a French family-owned pharmaceutical company that leverages life sciences, placing health and its balance at the heart of its corporate initiatives, innovations, and development for the benefit of patients worldwide.

      A pioneer and leader in human microbiota health by marketing the first probiotic strain, the global organization has developed its activities around three strategic areas: microbiota, women's health, and orphan diseases. It has also expanded its expertise by investing in other health areas, such as pain management; respiratory and ear, nose, and throat (ENT) pathways; and neurology.

      Present in 115 countries through its subsidiaries and partners, Biocodex emphasizes its territorial roots, which are central to its corporate social responsibility, producing in France for over 50 years across most of its value chain.

      The Biocodex global organization comprises 1,700 employees who share common values, embodied in their daily missions and rooted in the company's DNA.

      To learn more about Biocodex visit: www.biocodex.us/en/

      To learn more about DIACOMIT® (stiripentol) visit: www.diacomit.com

      INDICATION

      DIACOMIT (stiripentol) is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more. There are no clinical data to support the use of DIACOMIT as monotherapy in Dravet syndrome.

      IMPORTANT SAFETY INFORMATION

      CONTRAINDICATIONS

      None

      WARNINGS & PRECAUTIONS

      Somnolence

      DIACOMIT can cause somnolence. Monitor patients for somnolence, particularly when DIACOMIT is used concomitantly with other CNS depressants or clobazam, which is also known to cause somnolence.

      Decreased Appetite and Decreased Weight

      DIACOMIT can cause decreases in appetite and weight. The growth and weight of pediatric patients treated with DIACOMIT should be carefully monitored.

      Neutropenia and Thrombocytopenia

      DIACOMIT can cause significant declines in neutrophil and platelet counts. Hematologic testing should be obtained prior to starting treatment with DIACOMIT and then every 6 months.

      Withdrawal Symptoms

      As with most antiepileptic drugs (AEDs), DIACOMIT should be gradually withdrawn to minimize the risk of increased seizure frequency and status epilepticus.

      Risks in Patients with Phenylketonuria (PKU)

      DIACOMIT for oral suspension contains phenylalanine, which can be harmful to patients with PKU. Before prescribing DIACOMIT for oral suspension to a patient with PKU, consider the total daily intake of phenylalanine from all sources, including DIACOMIT for oral suspension. DIACOMIT capsules do not contain phenylalanine.

      Suicidal Behavior and Ideation

      AEDs, including DIACOMIT, increase the risk of suicidal thoughts or behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

      ADVERSE REACTIONS

      The most common adverse reactions that occurred in at least 10% of DIACOMIT-treated patients and more frequently than on placebo were somnolence, decreased appetite, agitation, ataxia, decreased weight, hypotonia, nausea, tremor, dysarthria, and insomnia.

      PREGNANCY

      There are no adequate data on the developmental risks associated with the use of DIACOMIT in pregnant women. Based on animal data, DIACOMIT may cause fetal harm.

      There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AEDs, such as DIACOMIT, during pregnancy. Physicians are advised to recommend that pregnant patients taking DIACOMIT enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry (information at www.aedpregnancyregistry.org). This can be done by calling the toll-free number 1-888-233-2334 and must be done by patients themselves or their caregiver. To report suspected adverse reactions, contact Biocodex at 1-866-330-3050 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

      Please see full DIACOMIT Prescribing Information at www.DIACOMIT.com.

      References: 1. Dravet C. The core Dravet syndrome phenotype. Epilepsia. 2011;52 Suppl 2:3-9.doi:10.1111/j.1528-1167.2011.02994. 2. Genton P, Velizarova R, Dravet C. Dravet syndrome: the long-term outcome. Epilepsia. 2011;52 Suppl 2:44-49. doi:10.1111/j.1528-1167.2011.03001. 3. Wu YW, Sullivan J, McDaniel SS, et al. Incidence of Dravet Syndrome in a US Population. Pediatrics. 2015;136(5):e1310-e1315. doi:10.1542/peds.2015-1807

      © 2025 Biocodex, Inc. All rights reserved. DIACOMIT® is a registered trademark of Biocodex, Inc.

      SOURCE Biocodex, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.